There are currently 57 clinical trials in Lancaster, Pennsylvania looking for participants to engage in research studies. Trials are conducted at various facilities, including Lancaster General Hospital, Urological Associates Of Lancaster, Lancaster Urology and GSK Investigational Site. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
Cardiac Implantable Electronic Device (CIED) Research Study
NCT05061862
Recruiting
The study is designed to collect data on Cardiovascular Implantable Electronic Device (CIED) implant and patient characteristics to support development of future CIED products and procedures.
Gender:
All
Ages:
18 years and above
Trial Updated:
11/07/2023
Locations: Lancaster General Hospital, Lancaster, Pennsylvania
Conditions: Arrhythmias, Cardiac, Bradycardia, Tachycardia
Register for Updates
Adjuvant Treatment Determined By Pathological Response To Neoadjvuant Nivolumab
NCT04013854
Recruiting
Subjects with resectable melanoma will receive neoadjuvant nivolumab followed by surgical resection. Post-operatively, subjects will receive open-label treatment with up to 1 year of adjuvant nivolumab or ipilimumab plus nivolumab as determined by pathologic response at the time of resection.
Gender:
All
Ages:
18 years and above
Trial Updated:
10/10/2023
Locations: Lancaster General Hospital, Lancaster, Pennsylvania
Conditions: Melanoma Stage III, Melanoma
Register for Updates
A Clinical Study to Evaluate Safety and Performance of PEEK-OPTIMA™ HA Enhanced.
NCT04416321
Recruiting
The purpose of this trial is to collect clinical outcomes including radiographic and CT outcomes in patients who undergo spinal fusion using the Keos Lumbar Interbody Fusion Device.
Gender:
All
Ages:
18 years and above
Trial Updated:
09/26/2023
Locations: Neurosurgical Associates of Lancaster, Lancaster, Pennsylvania
Conditions: Degenerative Disc Disease, Spondylolisthesis, Retrolisthesis
Register for Updates
Pharmacogenetics of Response to GLP1R Agonists
NCT05071898
Recruiting
Overweight/obese otherwise healthy volunteers will be recruited from the Old Order Amish population in Lancaster County, PA. Lancaster County, PA. Pharmacodynamic responses to GLP1R agonist will be assessed by conducting frequently sampled intravenous glucose tolerance tests (FSIGT) both before and after semaglutide for six weeks. The proposal proposes two specific aims: Specific Aim #1. To identify genetic variants associated with effects of a GLP1R agonist to enhance glucose-stimulated first... Read More
Gender:
All
Ages:
Between 18 years and 89 years
Trial Updated:
06/06/2023
Locations: Amish Research Clinic, Lancaster, Pennsylvania
Conditions: Obesity, Diabetes Type 2
Register for Updates
Study of ORIC-944 in Patients With Metastatic Prostate Cancer
NCT05413421
Recruiting
The purpose of this study is to establish recommended Phase 2 dose (RP2D) and/or maximum tolerated dose (MTD) and preliminary antitumor activity of ORIC-944 in patients with metastatic prostate cancer.
Gender:
Male
Ages:
18 years and above
Trial Updated:
04/28/2023
Locations: Keystone Urology Specialists, Lancaster, Pennsylvania
Conditions: Metastatic Prostate Cancer, Neuroendocrine Prostate Cancer
Register for Updates
A Study of Pemigatinib in Non-muscle Invasive Bladder Cancer Patients With Recurrent Low- or Intermediate-Risk Tumors
NCT03914794
Recruiting
This phase II trial studies how well Pemigatinib (an orally administered inhibitor of fibroblast growth factor receptors 1, 2, and 3) works in non-muscle invasive bladder cancer (NMIBC) patients with recurrent tumors and a prior history of low- or intermediate-risk NMIBC tumors. Participants will receive pemigatinib for 4-6 weeks prior to standard of care transurethral resection of bladder tumor (TURBT).
Gender:
All
Ages:
18 years and above
Trial Updated:
04/27/2023
Locations: Keystone Urology, Lancaster, Pennsylvania
Conditions: Bladder Cancer, NMIBC, Non-Muscle Invasive Bladder Cancer, Urothelial Carcinoma Recurrent
Register for Updates
Consistently Assess Signs and Symptom of Heart Failure
NCT05833581
Recruiting
Heart failure (HF) is a major public health problem. The New York Heart Association (NYHA) Functional Classification by a HF provider helps to guide their decisions in patient treatment. The purpose of this study is to further examine the NYHA Classification Guide that is designed to assist healthcare providers. The investigators will conduct the study in the outpatient clinic setting where adult patients with chronic heart failure are treated. HF providers will be asked to complete the NYHA cla... Read More
Gender:
All
Ages:
Between 18 years and 90 years
Trial Updated:
04/17/2023
Locations: Lancaster General Health/Penn Medicine, Lancaster, Pennsylvania
Conditions: Heart Failure, Heart Failure With Reduced Ejection Fraction, Heart Failure With Preserved Ejection Fraction
Register for Updates
Connect® Myeloid Disease Registry
NCT01688011
Recruiting
The purpose of the Connect® Myeloid disease registry is to provide unique insights into treatment decisions and treatment patterns as they relate to clinical outcomes of patients with myeloid diseases in routine clinical practice. This disease registry will also evaluate molecular and cellular markers that may provide further prognostic classification which may or may not be predictive of therapy and clinical outcomes.
Gender:
All
Ages:
18 years and above
Trial Updated:
10/25/2022
Locations: Lancaster Cancer Center, Lancaster, Pennsylvania +1 locations
Conditions: Myelodysplastic Syndromes, Primary Myelofibrosis, Leukemia, Myeloid, Acute
Register for Updates
Study of Relugolix in Men With Metastatic Castration-Sensitive Prostate Cancer or Non-Metastatic or Metastatic Castration-Resistant Prostate Cancer
NCT04666129
Recruiting
This study is being conducted to assess the safety and tolerability of relugolix with other agents approved for use in combination with androgen deprivation therapy (ADT) for a 12-week treatment period and an additional 40-week safety extension period in men with prostate cancer, either metastatic castration-sensitive prostate cancer (mCSPC) or non-metastatic or metastatic castration-resistant prostate cancer (nmCRPC or mCRPC).
Gender:
Male
Ages:
18 years and above
Trial Updated:
09/02/2022
Locations: Keystone Urology Specialists, Lancaster, Pennsylvania
Conditions: Metastatic Castration-Resistant Prostate Cancer, Metastatic Castration-Sensitive Prostate Cancer, Non-Metastatic Castration-Resistant Prostate Cancer
Register for Updates